New Biotech and Healthcare Platform based on US-India Innovation Corridor
New Biotech and Healthcare Platform based on US-India Innovation Corridor
Creating a 3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare.
New Biotech and Healthcare Platform based on US-India Innovation Corridor
Creating a 3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare.
$120B+
$120B+
$120B+
$120B+
of Immuno-Inflammatory Opportunity
of Immuno-Inflammatory Opportunity
For nearly a decade, Vyome has invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science.
Today, that focus is delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders.
For nearly a decade, Vyome has invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science.
Today, that focus is delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders.
Three Pillars. One Vision.
Three Pillars. One Vision.
Our approach combines world-class science, medical talent, and capital efficiency across the US and India to unlock innovation and impact in healthcare.
Our approach combines world-class science, medical talent, and capital efficiency across the US and India to unlock innovation and impact in healthcare.
Biotech & Pharma
Developing clinical-stage therapies for underserved conditions, wit near-term catalysts.
Developing clinical-stage therapies for underserved conditions, wit near-term catalysts.
Medical Devices
Acquiring and scaling proven innovations across markets.
Acquiring and scaling proven innovations across markets.
AI in Healthcare
Harnessing data and intelligence to transform patient outcomes.
Harnessing data and intelligence to transform patient outcomes.
Advancing treatments in areas of urgent need and low innovation.
At Vyome, we focus on immuno-inflammatory diseases that lack effective treatments, designing therapies that restore balance and improve lives.
At Vyome, we focus on immuno-inflammatory diseases that lack effective treatments, designing therapies that restore balance and improve lives.
Malignant Fungating Wounds
Bringing dignity back to late-stage cancer care
Bringing dignity back to late-stage cancer care
Bringing dignity back to late-stage cancer care
VT1953 is the first targeted therapy for MFW. Reducing odor, pain, and inflammation through a dual mechanism.
- 75% reduction in malodor early efficacy analysis
- No approved drugs exist today
- Orphan designation potential
Uveitis
A safer and steroid sparing path for Uvetis
A safer and steroid sparing path for Uvetis
A safer and steroid sparing path for Uvetis
VT1908, our non-steroidal eye drop, matches steroid performance in preclinical models—without the risks.
- Targets IMPDH to block immune cell overactivity
- Designed for patients who can’t use steroids
- Efficient regulatory path for rare indication
Drug-Resistant Acne
Next-gen acne treatment for the antibiotic resistant inflammatory acne
Next-gen acne treatment for the antibiotic resistant inflammatory acne
Next-gen acne treatment for the antibiotic resistant inflammatory acne
VB1953 treats resistant P. acnes strains while calming inflammation. Offering hope for millions failed by existing topicals.
- Dual action: DNA gyrase + TLR-MD2 inhibition
- Proven efficacy in clindamycin non-responders
- Best-in-class safety and proven efficacy profile in more than 550 patients including a large Phase 2 study
Positioned For Growth
Positioned For Growth
Immuno-inflammatory diseases alone represent a $120B+ market growing rapidly.
Immuno-inflammatory diseases alone represent a $120B+ market growing rapidly.
Patients with rare or resistant conditions are still underserved.
Patients with rare or resistant conditions are still underserved.
US–India innovation corridor is at a historic inflection point.
US–India innovation corridor is at a historic inflection point.
Vyome’s clean capital structure and platform model position us to deliver outsized impact.
Vyome’s clean capital structure and platform model position us to deliver outsized impact.
AI-centric healthcare platform initiatives.
AI-centric healthcare platform initiatives.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.